Key Points {#FPar1}
==========

Asenapine is a second-generation atypical antipsychotic drug with demonstrated efficacy in the treatment of mania associated with bipolar I disorder.Asenapine was also effective in the treatment of mixed states in patients with bipolar I disorder, as defined by the Diagnostic and Statistical Manual of Mental Disorders (DSM), 4th Edition, Text Revision, or major depressive disorder with mixed features, as defined by DSM-5.Several pharmacoeconomic studies have shown that asenapine is likely to be associated with lower healthcare costs and higher quality of life.

Introduction {#Sec1}
============

Bipolar disorder is a chronic affective condition characterised by episodes of mania and depression \[[@CR1]\]. Two major types of bipolar disorder have been defined: bipolar I and bipolar II \[[@CR2]\]. Manic episodes are the dominant feature of bipolar I; however, depressive episodes are also common. In bipolar II, manic symptoms have lower intensity and duration (hypomania), while depression is more pronounced. In addition, patients with bipolar disorder may experience episodes that combine the features of both mania and depression. The criteria for diagnosing these episodes vary. In the Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV, co-occurrence of full mania and depression for more than 1 week is defined as a mixed state (episode), whereas in the DSM-5 it has been replaced with a 'mixed features' specifier \[[@CR3]\].

In the general population, lifetime prevalence of bipolar spectrum disorders has been estimated at 2.4%, while the prevalence of bipolar I and II is approximately 0.6 and 0.4%, respectively \[[@CR4]\]. Bipolar disorder is associated with decreased cognitive function \[[@CR5]\] and professional ability, and increased risk of suicide and substance abuse \[[@CR4]\]. It is characterised by a high degree of comorbidity with other psychiatric conditions \[[@CR4]\] and places a significant burden on healthcare systems \[[@CR6]\]. In 2010, bipolar disorder was responsible for 0.5% of the total number of disability-adjusted life-years (DALYs) worldwide, or 5.0% of DALYs attributable to mental illness, surpassing Alzheimer's disease, Parkinson's disease and multiple sclerosis \[[@CR6]\].

Recommended treatments for bipolar disorder include lithium, antipsychotics, anxiolytics, antidepressants, anticonvulsants, electroconvulsive therapy and their various combinations \[[@CR7]\]. Atypical, or second-generation, antipsychotics are a class of drugs most commonly used in the treatment of bipolar disorder \[[@CR8]\]. Asenapine is an atypical antipsychotic drug used for the treatment of mania in bipolar disorder and schizophrenia. Its active ingredient, asenapine maleate, is a synthetic tetracyclic compound that is chemically distinct from other drugs in this class. In 2009, asenapine, under the brand name Saphris^®^, received marketing authorisation in the US for the treatment of manic or mixed episodes in adult patients with bipolar I disorder, as monotherapy or adjunctive treatment to lithium or valproate \[[@CR9]\]. Then, in 2010, it was approved in the EU for the treatment of moderate-to-severe manic episodes in adult patients with bipolar I disorder \[[@CR10]\]. In 2015, the US FDA also approved asenapine for the acute treatment of manic or mixed episodes of bipolar I disorder in paediatric patients (ages 10--17 years) \[[@CR11]\]. Asenapine has been approved for the treatment of mania associated with bipolar I disorder in multiple countries in North and South America, Europe, Asia and Oceania \[[@CR12]\]. Furthermore, asenapine is approved for the treatment of schizophrenia in the US, Canada, Australia, New Zealand and Argentina. In Europe, asenapine (brand name Sycrest^®^) is available as 5 and 10 mg rapidly dissolving tablets for sublingual administration.

The aim of this narrative review was to summarise the pharmacology, efficacy and safety of asenapine, and discuss its place in the treatment of bipolar disorder.

Pharmacokinetics {#Sec2}
================

Asenapine is available in 5 and 10 mg sublingual tablets for twice-daily administration. If administered sublingually, the bioavailability of a 5 mg dose of asenapine is approximately 35% \[[@CR13]\]. Exposure increases non-linearly and approximately 1.7-fold when the dose is doubled \[[@CR13]\]. It is recommended that eating and drinking is avoided for 10 min following administration \[[@CR13]\]. Drinking water 2 and 5 min after administration has been shown to decrease exposure by approximately 20 and 10%, respectively. These variations are within the range of intraindividual variability and may not be clinically significant \[[@CR14]\]. Taking asenapine within 30 min of consuming a high-fat meal has been shown to reduce exposure by approximately 20%, while consuming a high-fat meal 4 h after taking asenapine reduced exposure by approximately 13% \[[@CR15]\]. Supralingual administration has been shown to be essentially bioequivalent to sublingual administration based on area under the concentration-time curve values \[[@CR16]\]. If swallowed, the bioavailability of asenapine is approximately 2% \[[@CR17]\]. With sublingual administration, peak plasma concentration is reached within 0.5--1.5 h \[[@CR13]\]. Half-life is approximately 20 h \[[@CR16]\], and steady-state plasma levels are reached within 3 days of twice-daily administration \[[@CR13]\]. Asenapine is extensively metabolised, mostly by uridine diphosphate-glucuronosyltransferase 1-4 and cytochrome P450 (CYP) 1A2 \[[@CR13], [@CR18]\]; however, none of the metabolites can cross the blood--brain barrier \[[@CR17]\]. Approximately 90% of asenapine is excreted in faeces (50%) and urine (40%) within 96 h of administration \[[@CR13], [@CR18]\].

Fluvoxamine, a CYP1A2 inhibitor, has been shown to increase asenapine exposure, and coadministration should be avoided \[[@CR13]\]. In patients with severe hepatic impairment, asenapine exposure has been shown to be approximately seven times higher than in those with normal liver function, and commensurate dose titration is advised in this population. Renal impairment does not have any substantial effect on asenapine exposure \[[@CR13]\].

Asenapine increases blood concentrations of paroxetine \[[@CR13]\], and should be administered with caution in combination with drugs that are both substrates and inhibitors of CYP2D6 \[[@CR13]\].

Pharmacodynamics {#Sec3}
================

The exact mechanism of action of asenapine is unknown \[[@CR19]\]. Asenapine has been shown to interact with a wide range of receptors, including serotonin receptor subtypes 5-HT~1A~, 5-HT~1B~, 5-HT~2A~, 5-HT~2B~, 5-HT~2C~, 5-HT~5A~, 5-HT~6~ and 5-HT~7~; adrenoceptor subtypes α~1A~, α~2A~, α~2B~ and α~2C~; dopamine receptor subtypes D~1~, D~2L~, D~2S~, D~3~ and D~4~; and histamine receptor subtypes H~1~ and H~2~. At most of these, asenapine acts as an antagonist \[[@CR20]\], while it is likely a partial agonist at the 5-HT~1A~ receptor \[[@CR21]\]. Asenapine has a low affinity for muscarinic receptors (negative logarithm of the binding affinity \[p*K* ~i~\] ≤ 5) \[[@CR20]\]. Occupancy at the D~2~ dopamine receptor is believed to be responsible for the antimanic activity of asenapine \[[@CR19]\]. Compared with other atypical antipsychotic drugs, the affinity of asenapine for this receptor subtype is second only to that of aripiprazole \[[@CR20]\]. In addition, antagonist activity at 5-HT~1A~, 5-HT~1B~, 5-HT~2A~, 5-HT~2C~, 5-HT~5A~, 5-HT~6~ and 5-HT~7~ may contribute to the antimanic and antidepressant effects of asenapine \[[@CR19]\].

Therapeutic Efficacy {#Sec4}
====================

Randomised Controlled Trials and Extension Studies {#Sec5}
--------------------------------------------------

The evidence for the efficacy of asenapine in the treatment of bipolar disorder comes from a number of clinical studies that focused on patients with manic or mixed episodes (Table [1](#Tab1){ref-type="table"}).Table 1Efficacy outcomes in patients with bipolar I disorder and acute maniaPublication\
Length of observational period\
Source of fundingTreatment (*N*)YMRSCGI-BPMADRS \[mean (SD)\]Reduction in total score\
Mean (SD)Rate of response (%)Rate of remission (%)Overall severity\
Mean (SD)Mania \[mean (SD)\]Depression \[mean (SD)\]**Adults**McIntyre et al. \[[@CR22]\]\
3 weeks\
Schering-Plough, Pfizer Inc.ASE flexible dose bid\
(189)− 10.8 (0.8)^a,c^\*\*\*\
− 13.1 (0.8)^b,c^\*\*\*42.3\*\*40.2\*\*− 1.2 (0.1)^a,c^\*\*\
− 1.5 (0.1)^b,c^\*\*− 3.2 (0.5)^a,c^OLA flexible dose bid\
(188)− 12.6 (0.8)^a,c^\*\*\*\
− 13.9 (0.8)^b,c^\*\*\*50.0\*\*\*39.4\*− 1.4 (0.1)^a,c^\*\*\*\
− 1.6 (0.1)^b,c^\*\*− 4.2 (0.5)^a,c^\*\*PBO (103)− 5.5 (1.0)^a,c^\
− 7.4 (1.1)^b,c^25.222.3− 0.7 (0.13)^a,c^\
− 1.0 (0.2)^b,c^− 1.8 (0.7)^a,c^McIntyre et al. \[[@CR23]\]\
3 weeks\
Merck, Pfizer Inc.ASE flexible dose bid\
(183)− 11.5 (0.8)^a,c^\*\*^††^\
− 14.2 (0.9)^b,c^\*42.635.5− 1.2 (0.10)^a,c^\*^†^\
− 1.6 (0.11)^b,c^\*\*− 3.0 (0.4)^a,c^OLA flexible dose bid\
(203)− 14.6 (0.8)^a,c^\*\*\*\
− 16.1 (0.8)^b,c^\*\*\*54.7\*\*46.3\*− 1.5 (0.09)^a,c^\*\*\*\
− 1.7 (0.09)^b,c^\*\*\*-4.1 (0.4)^a,c^\*\*PBO (94)− 7.8 (0.8)^a^\
− 10.8 (1.2)^b,c^3430.9− 0.8 (0.13)^a,c^\
− 1.1 (0.15)^b,c^-1.9 (0.6)^a,c^McIntyre et al. \[[@CR33]\]\
9 weeks\
Schering-Plough, Pfizer Inc.ASE flexible dose bid\
(175)− 27.3 (0.64)77^†^75^†^− 2.6 (0.12)^c†^− 2.9 (0.11)^c†^− 0.1 (0.09)^c^\*− 3.6 (0.69)^c^\*OLA flexible dose bid\
(222)− 23.7 (0.55)8279− 2.4 (0.10)^c^− 2.8 (0.09)^c^0.0 (0.08)^c^− 2.4 (0.61)^c^McIntyre et al. \[[@CR34]\]\
40 weeks\
Schering-Plough (now Merck & Co. Inc.), Pfizer Inc.ASE flexible dose bid\
(76)− 25.8 (10.3)93.493.4− 3.2 (1.3)− 4.8 (6.5)OLA flexible dose bid\
(107)− 26.1 (8.4)95.295.2− 3.2 (1.1)− 3.2 (8.6)Landbloom et al. \[[@CR24]\]\
3 weeks\
Merck & Co. Inc.ASE 5 mg bid (120)− 14.4\*45.040.7− 1.6 (0.12)^c^\*− 5.8 (0.71)^c^\*\*ASE 10 mg bid (113)− 14.9\*\*46.943.4− 1.7 (0.12)^c^\*\*− 5.9 (0.73)^c^\*\*PBO (126)− 10.939.734.4− 1.1 (0.11)^c^− 3.2 (0.70)^c^Ketter et al. \[[@CR25]\]\
26 weeks\
Forest Research Institute Inc. (an Allergan affiliate), Merck & Co Inc.ASE 5 mg bid/ASE 5 mg bid (120)− 22.94443− 2.4ASE 10 mg bid/ASE 10 mg bid (113)− 22.04234− 2.3PBO/ASE 5 mg bid (126)− 22.35044− 2.3Szegedi et al. \[[@CR26]\]\
3 weeks\
Merck, Pfizer Inc.LI or VAL + ASE flexible dose bid (158)− 10.3 (0.8)\*34.233.5\*− 1.0 (0.09)\*\*− 1.1 (0.10)\*\*LI or VAL + PBO (166)− 7.9 (0.8)27.021.5− 0.7 (0.09)− 0.8 (0.09)Szegedi et al. \[[@CR26]\]\
12 weeks\
Merck, Pfizer Inc.LI or VAL + ASE flexible dose bid (158)− 12.7 (0.9)\*\*47.7\*43.2\*− 1.2 (0.11)\*− 1.5 (0.12)\*\*\*LI or VAL + PBO (166)− 9.3 (0.9)34.430.1− 0.8 (0.11)− 1.0 (0.11)**Paediatric patients**Findling et al. \[[@CR27]\]\
3 weeks\
Merck & Co. Inc.ASE 2.5 mg bid (101)− 12.8\*\*\*42\*--0.6 (− 0.9, − 0.3)^d^\*\*\*ASE 5 mg bid (98)− 14.9\*\*\*54\*\*\*--0.7 (− 0.9, − 0.4)^d^\*\*\*ASE 10 mg bid (98)− 15.8\*\*\*52\*\*\*--0.7 (− 1.0, − 0.4)^d^\*\*\*PBO (98)9.628Findling et al. \[[@CR28]\]\
26 weeks\
Merck & Co. Inc., Allergan Inc.ASE flexible dose bid (321)− 6.95068.5*ASE* asenapine, *bid* twice daily, *CGI-BP* Clinical Global Impression--Bipolar, *LI* lithium, *MADRS* Montgomery--Åsberg Depression Rating Scale, *OLA* olanzapine, *PBO* placebo, *VAL* valproate, *SD* standard deviation, *YMRS* Young Mania Rating Scale\**p* ≤ 0.05, \*\**p* ≤ 0.01, \*\*\**p* \< 0.001 vs. placebo^†^ *p* \< 0.05, ^††^ *p* \< 0.01, ^†††^ *p* \< 0.001 vs. active comparator^a^Last observation carried forward^b^Mixed-effect model repeat measurement^c^Standard error^d^Difference vs. placebo, 95% confidence interval

### Asenapine Versus Placebo {#Sec6}

An evaluation of the efficacy of flexible-dose asenapine was provided in two randomised, placebo- and olanzapine-controlled clinical trials \[[@CR22], [@CR23]\]. In both studies, mean total Young Mania Rating Scale (YMRS) scores were significantly reduced at the end of the treatment period in patients who received asenapine compared with those who received placebo \[[@CR22], [@CR23]\]. Significant improvements were evident early in the course of treatment (day 2) \[[@CR22], [@CR23]\]. The rates of response (defined as ≥ 50% reduction in total YMRS score) and remission (defined as total YMRS score ≤ 12 after treatment) were significantly higher with asenapine compared with placebo in one of the studies \[[@CR22]\], while they were not significantly different in the other \[[@CR23]\]. Asenapine was associated with significant reductions in mean Clinical Global Impression--Bipolar (CGI-BP) scores compared with placebo in both studies \[[@CR22], [@CR23]\]. After 3 weeks of therapy, asenapine did not improve mean Montgomery--Åsberg Depression Rating Scale (MADRS) scores in either study \[[@CR22], [@CR23]\]. In one study, shifts in mean MADRS score from ≤ 8 at baseline to ≥ 16 after 3 weeks were reported in 1.6% of patients receiving asenapine, 1.1% of patients receiving olanzapine, and 2.0% of patients receiving placebo \[[@CR22]\], while in another study, these percentages were 0, 1.0 and 4.0%, respectively \[[@CR23]\].

Asenapine was also effective at improving the symptoms of bipolar disorder when administered as a 5 or 10 mg twice-daily fixed dose for 3 weeks \[[@CR24]\]. Both doses produced statistically significant reductions in mean total YMRS scores at day 4 and at the end of the treatment period when compared with placebo \[[@CR24]\]. Similarly, both doses were associated with significant reductions in mean total CGI-BP scores at day 4 and at the end of the treatment period (Table [1](#Tab1){ref-type="table"}) \[[@CR24]\]. Furthermore, mean MADRS scores were significantly reduced with both doses of asenapine at day 7 and at the end of the study \[[@CR24]\].

Patients who completed the above 3-week placebo-controlled study could enter a 26-week uncontrolled extension. Those who received placebo during the 3-week trial were assigned to asenapine 5 mg twice daily \[[@CR25]\]. The positive effects of asenapine on efficacy parameters were maintained at the end of the extension study \[[@CR25]\]. Mean total YMRS scores were further decreased compared with the extension study baseline in patients who received 5 and 10 mg of asenapine, as well as in those who switched to asenapine after placebo \[[@CR25]\]. Improvements in the rates of YMRS response and remission were observed in all treatment groups, as were improvements in the CGI-BP scores \[[@CR25]\].

A 3-week, randomised, placebo-controlled clinical trial, plus a 40-week placebo-controlled extension study conducted in patients with bipolar I disorder with manic or mixed episodes, showed that asenapine was effective in reducing symptoms when used as add-on therapy to lithium or valproate \[[@CR26]\]. At week 3, a significant reduction in mean total YMRS scores was observed in patients receiving asenapine compared with those receiving placebo \[[@CR26]\]. No significant difference in mean YMRS total score was detected between patients receiving lithium and those receiving valproate \[[@CR26]\]. Furthermore, YMRS response rate with asenapine was not significantly different to that with placebo at 3 weeks; however, at 12 weeks the response rate with asenapine was significantly higher. YMRS remission rates with asenapine were significantly higher than with placebo at weeks 3 and 12 \[[@CR26]\]. Patients treated with asenapine had significantly lower mean total CGI-BP scores at weeks 3 and 12 compared with those who received placebo \[[@CR26]\]. Due to the low number of patients recruited in the extension study, no robust conclusions about the efficacy of adjunctive treatment with asenapine could be drawn \[[@CR26]\].

Asenapine has been shown to be effective in the treatment of manic or mixed episodes in paediatric patients aged 10--17 years \[[@CR27], [@CR28]\]. In a 3-week, randomised, placebo-controlled study, asenapine was associated with statistically significant reductions in mean total YMRS score at day 21. Reductions were observed from day 4 \[[@CR27]\]. The rates of YMRS response were higher in patients receiving asenapine compared with placebo at day 21 \[[@CR27]\]. At day 21, asenapine was associated with significant reductions in mean CGI-BP scores from baseline \[[@CR27]\]. A subsequent 50-week, placebo-controlled extension study reported that these improvements were maintained at week 26 (Table [1](#Tab1){ref-type="table"}) \[[@CR28]\].

Several non-randomised studies assessed the efficacy of asenapine in the treatment of elderly patients with bipolar disorder. In a 3-week, open-label clinical study, monotherapy with asenapine was shown to be effective in the treatment of manic or mixed patients \[[@CR29]\]. Mean total YMRS, CGI-BP mania and total MADRS scores were significantly reduced at the end of the study period \[[@CR29]\]. A 4-week study of the effectiveness of asenapine in the acute treatment of bipolar disorder in consecutively admitted elderly patients showed significant reductions from baseline in mean total YMRS, all mean individual YMRS items and mean total CGI-BP with asenapine \[[@CR30]\]. Additionally, another study assessed the efficacy of adjunctive treatment with asenapine in elderly patients with bipolar I and acute manic or mixed episodes \[[@CR31]\]. At the end of the treatment period, significant reductions from baseline were observed in mean Brief Psychiatric Rating Scale \[BPRS\] (*p* \< 0.05), total CGI (*p* \< 0.01), CGI-BP mania (*p* \< 0.05) and depression (*p* \< 0.01) scales \[[@CR31]\].

A naturalistic observational study assessed the efficacy of asenapine in patients with bipolar I and schizoaffective disorder \[[@CR32]\]. After 4 weeks of treatment, significant reductions in mean Hamilton Rating Scale for Depression (HAM-D) and mean total YMRS scores were observed \[[@CR32]\].

### Asenapine Versus Olanzapine {#Sec7}

In one of the studies by McIntyre and colleagues described above, post hoc analyses were performed to evaluate the difference in efficacy between asenapine and olanzapine. When the last observation carried forward (LOCF) method was used, reductions in YMRS scores and CGI-BP mania severity scores were greater with olanzapine than with asenapine (*p* = 0.004 and *p* = 0.035, respectively). However, improvements in YMRS and CGI-BP scores were not significantly different with asenapine and olanzapine when the Mixed-Effect Model Repeated Measure model was used. Similarly, improvements in mean MADRS total score were not different in patients receiving asenapine versus olanzapine. It should be noted that the study was not powered for comparison between the active treatments \[[@CR23]\].

Patients who completed one of the studies by McIntyre and colleagues and could benefit from continued treatment were recruited in a 9-week extension, designed to compare asenapine with olanzapine. At the end of the observational period, asenapine met the prespecified criteria for non-inferiority to olanzapine in YMRS total score, CGI-BP mania and overall illness severity scores, and YMRS response and remission rates \[[@CR33]\]. Shifts in mean MADRS score from ≤ 8 at baseline to ≥ 16 at the end of the study were reported in 2.3% of patients who received asenapine and 5.0% of those who received olanzapine \[[@CR33]\]. Patients who completed the 9-week extension study were eligible to enter a second, 40-week extension study. At the end of the treatment period, similar reductions in YMRS scores were observed in patients treated with asenapine and those treated with olanzapine. No statistically significant differences in YMRS response and remission rates, as well as CGI-BP severity scores, were detected (Table [1](#Tab1){ref-type="table"}) \[[@CR34]\]. At the end of the study, no patients receiving asenapine had a shift in mean MADRS score from ≤ 8 at baseline to ≥ 16, while 3.0% of patients receiving olanzapine experienced such shifts \[[@CR34]\].

Asenapine Versus Other Antipsychotic Drugs {#Sec8}
------------------------------------------

The efficacy of asenapine was compared with that of several other antipsychotic drugs in a single-blind clinical study that included 155 patients with bipolar I disorder and a current manic episode \[[@CR35]\]. Based on clinical judgement, particularly taking into account such factors as concomitant conditions and specific symptoms, 44 patients were assigned to haloperidol 3--9 mg/day, 50 patients to olanzapine 15--30 mg/day, 16 patients to risperidone 4--9 mg/day, 13 patients to quetiapine 600--1000 mg/day, 16 patients to aripiprazole 20--30 mg/day and 16 patients to asenapine 10--20 mg/day. The outcomes were evaluated after 4 and 7 days of treatment. After 4 days of therapy, patients who received asenapine had significantly lower total YMRS scores compared with those who received haloperidol (*p* = 0.001). After 7 days of therapy, those who received asenapine had lower YMRS scores than those receiving haloperidol (*p* = 0.001), as well as those receiving olanzapine (*p* = 0.047). Also after 7 days, patients treated with asenapine achieved YMRS clinical response more often than those treated with haloperidol and risperidone (*p* \< 0.05), as well as YMRS remission more often than those treated with aripiprazole, quetiapine and haloperidol (*p* \< 0.05). The authors concluded that asenapine was more effective in the treatment of acute mania than other antipsychotic drugs \[[@CR35]\].

Post Hoc and Pooled Data Analyses {#Sec9}
---------------------------------

An analysis of pooled data from the two placebo-controlled clinical trials of asenapine and olanzapine showed that both asenapine and olanzapine significantly improved each of the 11 individual items comprising the YMRS, compared with placebo at day 21. Furthermore, both treatments were associated with significant improvements in individual YMRS items, including disruptive-aggressive behaviour, content, irritability, elevated mood, sleep and speech at day 2 \[[@CR36]\].

A post hoc analysis of pooled data from three randomised active-controlled trials of asenapine versus olanzapine was conducted to assess the impact of early response on treatment outcome \[[@CR37]\]. An improvement of ≥ 15% in the total YMRS score was observed in 28 and 51% of patients who received asenapine at days 2 and 4, respectively, while a similar improvement was observed in 32% of patients who received olanzapine at day 2 and 60% of patients at day 4. Moreover, an improvement in YMRS total score at day 2 was predictive of response and remission after 3 weeks of treatment with asenapine, as well as olanzapine, and an improvement of ≥ 1 point in CGI-BP overall illness at day 4 was predictive of response and remission at the end of week 3, while similar improvement in the CGI-BP mania severity subscore was predictive at day 2. The association between early response and subsequent overall response and remission was stronger with asenapine than with olanzapine \[[@CR37]\].

The efficacy of asenapine and olanzapine in the treatment of patients with mixed episodes was analysed and compared in a post hoc analysis of two pivotal clinical trials that included 960 participants. MADRS or Positive and Negative Syndrome Scale (PANSS) items were used to detect the presence of mixed episodes. In this cohort, 34, 18 and 4.3% of patients had mild, moderate and severe depressive symptoms, respectively. MADRS remission (score ≤ 12) rate with asenapine was stable at 64--67%, regardless of baseline severity, while with olanzapine and placebo it decreased in patients with higher baseline MADRS score (63--38, and 49--25%, respectively). At day 2 and across all severity groups, the reduction in YMRS score was significantly greater in patients who received asenapine compared with those who received placebo. On the other hand, the reduction in YMRS score with olanzapine was significantly greater compared with placebo only in patients with mild and moderate symptoms. With asenapine, YMRS scores continued to decrease over the entire treatment period \[[@CR38]\].

A post hoc analysis of patients with bipolar I disorder and clinically significant depressive symptoms (which included patients who had a YMRS total score of ≥ 20), who participated in placebo-controlled clinical trials of asenapine and olanzapine, demonstrated that asenapine was associated with a significant reduction in mean MADRS score compared with placebo, while the effect of olanzapine was not significantly different from that of placebo \[[@CR39]\]. Another post hoc analysis that relied on the same data confirmed these findings. Compared with placebo, asenapine significantly improved the following depressive symptoms: sadness, reduced sleep, reduced appetite and lassitude at day 7, whereas olanzapine significantly improved lassitude when compared with placebo at day 7. Asenapine was significantly more effective than olanzapine in improving sadness, concentration difficulties, inability to feel, and pessimistic thoughts at day 7. At day 21, asenapine was associated with significant improvements in sadness, inner tension and inability to feel compared with placebo. Furthermore, asenapine was significantly more effective in improving inability to feel than olanzapine at day 21. Olanzapine was not associated with improvement in any of the symptoms of depression at day 21 \[[@CR40]\].

A post hoc analysis of clinical trials of asenapine has shown that it improved health-related quality of life in patients with bipolar I disorder experiencing mixed episodes compared with placebo and olanzapine \[[@CR41]\].

Tolerability and Safety {#Sec10}
=======================

In patients with bipolar disorder, common adverse events (incidence of ≥ 5% and at least twice that with placebo) associated with asenapine monotherapy include somnolence (24 vs. 6%; number needed to harm \[NNH\] = 6; 95% confidence interval \[CI\] 5--9), dizziness (11 vs. 3%; NNH = 13; 95% CI 9--25), extrapyramidal symptoms other than akathisia (7 vs. 2%; NNH = 20; 95% CI 13--56) and increased bodyweight (24 vs. \< 1%; NNH = 6; 95% CI 5--9), while with asenapine add-on therapy, these common adverse events are somnolence (22% vs. 10%; NNH = 9; 95% CI 5--25) and oral hypoesthesia (5 vs. 0%; NNH = 20; 95% CI 12--63) \[[@CR42]\]. In short-term clinical studies, adverse events led to discontinuation of treatment in 10% of patients receiving asenapine monotherapy and approximately 6% of patients receiving placebo, while in the study of asenapine add-on therapy, these percentages were 16 and 11%, respectively \[[@CR14]\].

Although somnolence is the most common adverse event associated with asenapine, in short-term clinical studies in patients with bipolar disorder, the incidence of somnolence was lower with asenapine monotherapy (23.8%) than with olanzapine monotherapy (26.4%) \[[@CR14]\].

The incidence of extrapyramidal adverse events in patients with bipolar disorder in short-term trials was 10.0, 4.4 and 9.4% with asenapine, placebo and olanzapine, respectively \[[@CR43]\], and 15.7, 12.7 and 16.2%, respectively, in long-term trials \[[@CR43]\].

Asenapine is known to cause oral hypoesthesia, which has been attributed to its local anaesthetic activity \[[@CR42]\]. Oral hypoesthesia commonly resolves within 1 h \[[@CR13]\]. In clinical trials of asenapine monotherapy for acute mania in patients with bipolar disorder, the incidence of oral hypoesthesia was 4% in patients who received asenapine compared with \< 1% in those who received placebo (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR42]\]. The rate of discontinuation due to oral hypoesthesia was 1.1% among patients receiving asenapine compared with 0% for placebo (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR42]\].Fig. 1Frequency of selected adverse events in clinical trials of asenapine in patients with bipolar I disorder. *AE* adverse event, *SAE* serious adverse event

The summary of product characteristics for asenapine \[[@CR13]\] contains a number of warnings, one of which is for orthostatic hypotension and syncope. In short-term clinical studies that evaluated asenapine monotherapy, dizziness was reported by 11% of patients treated with asenapine compared with 3% of patients receiving placebo, and 4 and 2% of patients, respectively, in studies that evaluated add-on treatment with asenapine for mania associated with bipolar I disorder. Syncope occurred in 0.03% of patients receiving asenapine monotherapy and 0% of those receiving placebo \[[@CR42]\]. Asenapine does not appear to be associated with clinically relevant prolongation of the QT interval. Nevertheless, asenapine should be used with caution in patients with cardiovascular disease, hereditary predisposition to QT interval prolongation or those receiving medications known to cause this risk factor \[[@CR13]\]. Another warning refers to the risk of hyperglycaemia and exacerbation of pre-existing diabetes, and monitoring is recommended in at-risk patients \[[@CR13]\]. In short-term clinical trials, elevations of fasting serum glucose, total cholesterol and triglycerides were observed in 4.9% (NNH = 38), 8.7% (NHH = 1000) and 15.2% (NHH = 27) of patients who received asenapine monotherapy following treatment, respectively, compared with 2.2, 8.6 and 11.4% of patients who received placebo, respectively \[[@CR42]\]. In short-term clinical trials, patients who received asenapine monotherapy had a mean increase in bodyweight of 1.3 kg, while those who received placebo gained 0.2 kg. Clinically relevant increases in bodyweight (≥ 7%) occurred in 5.8% of patients on asenapine monotherapy and 0.5% of patients on placebo. In a 40-week extension study, patients continuously treated with asenapine gained a mean of 3.5 kg, while patients treated with olanzapine gained 6.0 kg (Fig. [2](#Fig2){ref-type="fig"}). Clinically relevant weight gain was observed in 39.2% of patients continuously treated with asenapine compared with 55.1% of patients treated with olanzapine \[[@CR42]\]. Hyperprolactinaemia has been reported in some patients treated with asenapine. In short-term clinical trials, 2.3% (NHH = 63) of patients with bipolar disorder who received asenapine monotherapy had prolactin levels ≥ 4 times the upper limit of the normal range compared with 0.7% of those who received placebo \[[@CR42]\]. However, clinically significant adverse events due to hyperprolactinaemia associated with asenapine use are rare \[[@CR13]\].Fig. 2Frequency of serious adverse events in clinical trials of asenapine in patients with bipolar I disorder. *AE* adverse event, *EPS* extrapyramidal system, *SAE* serious adverse event

Pooled Data Analyses {#Sec11}
--------------------

An analysis of pooled data from two 3-week monotherapy trials and one 12-week add-on therapy trial showed that the incidence of somnolence associated with asenapine, olanzapine and placebo was 23.8, 26.4 and 6.4%, respectively. In patients who participated in monotherapy trials, the NNH (95% CI) for somnolence was 6 (4--9) with asenapine and 5 (4--7) with olanzapine. There was no significant difference in the time to onset of somnolence between the three treatment groups, while median duration of somnolence was 7, 8.5 and 5 days with asenapine, olanzapine and placebo, respectively. In the add-on therapy trial, the incidence of somnolence was 24.1% (NNH = 7; 95% CI 5--18) with asenapine compared with 10.2% with placebo. While time to onset did not differ between the treatment groups, duration of somnolence was longer in patients treated with asenapine (12.5 vs. 7.0 days) \[[@CR44]\].

Current Use in Clinical Practice {#Sec12}
================================

Asenapine is currently approved in the EU for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults \[[@CR13]\], while in the US, it is approved for the treatment of manic or mixed episodes of bipolar I disorder in adult and paediatric patients (age 10--17 years) \[[@CR9], [@CR11]\]. Clinical practice guidelines from the British Association for Psychopharmacology also recommend asenapine for this indication \[[@CR7]\], while guidelines for the treatment of major depressive episodes with mixed features by Stahl and colleagues recommend asenapine monotherapy as first-line treatment, along with lurasidone, quetiapine, quetiapine XR, aripiprazole and ziprasidone \[[@CR45]\]. Those cases may be particularly difficult to treat given their poor response to antidepressant drugs \[[@CR46]\].

Available evidence, including clinical trials and post hoc and pooled data analyses, suggests that asenapine is effective in the acute and long-term treatment of manic and, in particular, mixed episodes in patients with bipolar disorder. The goal of the MANACOR study (MANía Aguda y COnsumo de Recursos, acute mania and health resource consumption), which combined prospective and retrospective data collection and analysis, was to estimate the healthcare resource consumption and direct costs associated with manic episodes in real-world clinical practice in Spain \[[@CR47]\]. An analysis of data revealed the prescribing patterns associated with asenapine \[[@CR48]\]. Patients who were prescribed adjunctive asenapine tended to have less severe manic episodes, fewer psychotic manifestations and a more complex clinical history, in particular, of mixed episodes and sexual dysfunction, compared with those receiving other adjunctive antipsychotics \[[@CR48]\]. The DSM-5 defines mixed states more broadly than DSM-IV, allowing for mania with some depressive symptoms, depression with some manic symptoms, and hypomania with some depressive symptoms, which are diagnosed using a dimensional approach \[[@CR49], [@CR50]\]. The IMPACT (Investigating Manic Phases And Current Trends) of Bipolar international multicentre study utilised a 54-item online questionnaire, which was administered to 700 patients with bipolar I disorder, to assess the specific phenomenology of depressive symptoms in patients who had a manic episode with depressive features, as defined by the DSM-5 \[[@CR3]\]. The results indicate that patients who reported to have at least three depressive symptoms during a manic episode also commonly experienced anxiety with irritability or agitation \[[@CR3]\]. Based on these findings, as well as those from post hoc analyses of the pivotal clinical trials of asenapine \[[@CR51]\], some authors suggest that a combination of anxiety, irritability and agitation symptoms represents the most sensitive approach to detecting mixed states \[[@CR52]\].

Although oral hypoesthesia was relatively uncommon in randomised controlled trials of asenapine, when healthy male participants were asked about oral hypoesthesia in a pharmacokinetics study, 22.2% reported experiencing this adverse event \[[@CR16]\]. These data suggest that in real-world practice, the prevalence of oral hypoesthesia may in fact be much higher than in randomised clinical trials. It is recommended that patients are informed about the possibility of this adverse event before taking asenapine to avoid any negative effect on adherence \[[@CR42]\].

The available data on the safety of asenapine suggest that it is less likely to weight gain than olanzapine. This is particularly important because weight gain is one of the adverse events most likely to result in treatment non-compliance \[[@CR53]\]. Furthermore, asenapine has been shown to significantly improve health-related quality of life compared with olanzapine \[[@CR41]\]. Pharmacoeconomic analyses support this conclusion and suggest that the use of asenapine is likely to reduce healthcare-related costs in patients with bipolar disorder.

Discussion {#Sec13}
==========

Asenapine is a second-generation atypical antipsychotic drug that is approved for the treatment of manic episodes in patients with bipolar I disorder. It is available in 5 and 10 mg tablets for twice-daily sublingual administration. The results of a study that compared 5 mg asenapine twice daily and 10 mg asenapine once daily at bedtime suggest that the latter regimen, by reducing the rate of daytime sedation, may improve adherence \[[@CR54]\]. Patients are recommended to avoid eating and drinking for 10 min after taking asenapine, and eating a meal within 4 h has been shown to reduce exposure. Therefore, adherence to asenapine may be negatively affected by the limitations on when and how often it must be taken.

The efficacy of asenapine in the treatment of manic episodes in patients with bipolar I disorder has been the subject of several studies. Asenapine was consistently associated with improvements in acute mania, as measured by YMRS and CGI-BP in paediatric (age 10--17 years), adult and elderly patients. A number of long-term extension studies have also shown that the effects of asenapine are maintained for up to 40 weeks. The efficacy of asenapine was either similar or superior to that of olanzapine. Of note, asenapine did not produce significant improvements in MADRS scores in randomised controlled trials; however, in a post hoc analysis, asenapine was shown to be effective in reducing the symptoms of depression in patients with bipolar I disorder and a current manic episode. In order to properly assess the place of asenapine in the antipsychotic armamentarium, additional direct comparisons with other antipsychotic drugs, in the acute as well as long-term treatment of mania, are required.

The use of asenapine is associated with a number of adverse events, including somnolence, dizziness, extrapyramidal symptoms and increased bodyweight. In a meta-analysis of clinical trials of various antipsychotics, the authors concluded that asenapine presents a mid-level risk of weight gain compared with other drugs in this class. Clozapine and olanzapine were found to have the highest risk of weight gain, while aripiprazole, lurasidone and ziprasidone are associated with a lower risk of weight gain than asenapine \[[@CR55]\]. The Summary of Product Characteristics for asenapine contains several warnings, including a warning for orthostatic hypotension and syncope, and for hyperglycaemia and exacerbation of pre-existing diabetes. The risk of blood lipid and glucose abnormalities associated with asenapine is relatively low and is less serious than with clozapine and olanzapine \[[@CR56]\]. Another adverse event observed with asenapine is oral hypoesthesia. Although the frequency of this event was relatively low in randomised controlled trials, it is likely higher in real-world practice. The safety and tolerability profile of asenapine appears to be similar to that of olanzapine. As with efficacy, additional studies that directly compare the safety of asenapine with other antipsychotic drugs may allow for a more comprehensive assessment.

An economic evaluation of the use of asenapine in the treatment of patients with mixed episodes associated with bipolar I disorder, based on data from the Ares trial programme and extrapolated using a Markov model, was conducted \[[@CR57]\]. Over the course of 5 years, asenapine generated 0.0187 more quality-adjusted life-years (QALYs) compared with olanzapine for every additional ₤24. This was primarily driven by an earlier response to asenapine \[[@CR57]\]. This model was adapted for use in another study that aimed to estimate the cost effectiveness of asenapine compared with olanzapine in the treatment of patients with bipolar I disorder and a current manic episode in the context of Italian National Health Service \[[@CR58]\]. Asenapine was found to be associated with lower direct costs, which was mostly due to the savings from hospitalisations avoided. Asenapine was also associated with higher quality of life compared with olanzapine \[[@CR58]\]. The cost effectiveness of asenapine therapy for mania in patients with bipolar I disorder was also evaluated in the context of Canadian practice, using a decision-tree account of the probability of extrapyramidal symptoms, switching to a different antipsychotic drug and gaining weight, and the Markov model to account for long-term metabolic complications such as diabetes, hypertension, coronary heart disease and stroke. Asenapine was associated with lower costs and generated more QALYs \[[@CR59]\]. An analysis of a large US medical insurance database that included claims 6 months before and after the introduction of asenapine was carried out to assess the healthcare utilisation costs \[[@CR60]\]. While pharmacy-related costs increased, these costs were offset by the reduced costs in admissions and emergency department visits following the introduction of asenapine \[[@CR60]\]. Asenapine also reduced costs associated with the management of manic episodes in the MANACOR study \[[@CR47]\].

Conclusions {#Sec14}
===========

Asenapine is effective in the acute and long-term treatment of manic and mixed episodes associated with bipolar disorder. It produces a rapid reduction in the symptoms of mania and is particularly effective in the treatment of mixed episodes. Furthermore, asenapine is effective in alleviating the symptoms of depression in patients with bipolar I disorder during mania. The risk of weight gain is lower with asenapine than with olanzapine. In addition, asenapine has been shown to improve health-related quality of life and reduce hospitalisation costs.
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